Except for WT1, alternative intracellular antigens preferentially expressed by AML, such as PRAME,77 telomerase,78 HMMR/Rhamm,79 and the mutated form of NPM180 have shown promise in clinical trials or preclinical research with engineered TCR‐T cells. Here, WT1 is linked to acute myeloid leukemia.